SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma enters into in-licensing agreement with Biocon

24 Dec 2025 Evaluate

Ajanta Pharma has entered into an in-licensing agreement with Biocon for Semaglutide, a GLP-1 receptor agonist. Under the agreement, Biocon will supply Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, the Middle East and Central Asia.

Semaglutide, the GLP-1 receptor agonist, is to improve glycaemic control in adults. The product patent expires in most of these markets in March 2026. Ajanta plans to commercialize the products after receiving the regulatory approvals, which are expected in late 2026 or early 2027.

Ajanta has been one of the pioneers among Indian companies to build a strong branded generic business with own field force in over 30 countries across Africa, South-East Asia, Central Asia and the Middle East. In these markets, company has presence in a wide range of therapeutic segments like, Cardiology, Antidiabetic, Ophthalmology, Antibiotic, Antimalarial, Pain, Gynaecology, Paediatric and General Health products.

Ajanta Pharma is a specialty pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa.

Ajanta Pharma Share Price

2908.95 13.10 (0.45%)
15-Apr-2026 10:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1671.20
Dr. Reddys Lab 1218.00
Cipla 1225.75
Zydus Lifesciences 930.65
Lupin 2337.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×